ExoPTEN, which is advancing towards first-in-human trials. The study demonstrated that ExoPTEN significantly enhances motor function recovery and improves blood flow at spinal cord injury sites, ...

Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...

Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...

Sorghum is an increasingly important crop for animal and human nutrition, especially in arid and semi-arid regions, due to ...